Literature DB >> 32325221

The design can limit PRECIS-2 retrospective assessment of the clinical trial explanatory/pragmatic features.

Rafael Dal-Ré1, Anthonius de Boer2, Stefan K James3.   

Abstract

Keywords:  Assessment; Blinding; Clinical trials; Explanatory trials; PRECIS-2; Placebo; Pragmatic trials; Reporting bias

Year:  2020        PMID： 32325221     DOI： 10.1016/j.jclinepi.2020.03.027

Source DB:  PubMed          Journal:  J Clin Epidemiol        ISSN： 0895-4356            Impact factor:   6.437


× No keyword cloud information.
  3 in total

1.  The PRECIS-2 tool seems not to be useful to discriminate the degree of pragmatism of medicine masked trials from that of open-label trials.

Authors:  Rafael Dal-Ré
Journal:  Eur J Clin Pharmacol       Date:  2020-10-26       Impact factor: 2.953

Review 2.  A review of pragmatic trials found a high degree of diversity in design and scope, deficiencies in reporting and trial registry data, and poor indexing.

Authors:  Stuart G Nicholls; Kelly Carroll; Spencer Phillips Hey; Merrick Zwarenstein; Jennifer Zhe Zhang; Hayden P Nix; Jamie C Brehaut; Joanne E McKenzie; Steve McDonald; Charles Weijer; Dean A Fergusson; Monica Taljaard
Journal:  J Clin Epidemiol       Date:  2021-03-28       Impact factor: 6.437

3.  Pragmatic trials of pain therapies: a systematic review of methods.

Authors:  David Hohenschurz-Schmidt; Bethea A Kleykamp; Jerry Draper-Rodi; Jan Vollert; Jessica Chan; McKenzie Ferguson; Ewan McNicol; Jules Phalip; Scott R Evans; Dennis C Turk; Robert H Dworkin; Andrew S C Rice
Journal:  Pain       Date:  2022-01-01       Impact factor: 6.961
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.